INTRODUCTION: Ovarian cancer ascitic fluid, which contains malignant cells, is usually present in women with an advanced stage disease. There are currently no effective therapies for the treatment of ovarian cancer ascitic fluid. We developed a new therapeutic strategy to target expression of the diphtheria toxin fragment A gene in ovarian tumor cells under the control of H19 regulatory sequences. CASE PRESENTATION: A 64-year-old Caucasian woman was diagnosed with a stage IIIc epithelial ovarian cancer. She suffered from progressive disease, accumulation of malignant ascites that needed to be drained weekly, abdominal pain, vomiting, anorexia and severe weakness. Infusion of the diphtheria toxin A chain-H19 plasmid into the peritoneum of our patient resulted in complete resolution of the ascites with minimum adverse events. CONCLUSION: On the basis of this preliminary experience, we are currently conducting an extensive Phase I study on a larger number of patients in order to assess the safety and preliminary efficacy of this novel patient-oriented treatment approach.
INTRODUCTION:Ovarian cancer ascitic fluid, which contains malignant cells, is usually present in women with an advanced stage disease. There are currently no effective therapies for the treatment of ovarian cancer ascitic fluid. We developed a new therapeutic strategy to target expression of the diphtheria toxin fragment A gene in ovarian tumor cells under the control of H19 regulatory sequences. CASE PRESENTATION: A 64-year-old Caucasian woman was diagnosed with a stage IIIc epithelial ovarian cancer. She suffered from progressive disease, accumulation of malignant ascites that needed to be drained weekly, abdominal pain, vomiting, anorexia and severe weakness. Infusion of the diphtheria toxin A chain-H19 plasmid into the peritoneum of our patient resulted in complete resolution of the ascites with minimum adverse events. CONCLUSION: On the basis of this preliminary experience, we are currently conducting an extensive Phase I study on a larger number of patients in order to assess the safety and preliminary efficacy of this novel patient-oriented treatment approach.
Authors: E S Massuda; E J Dunphy; R A Redman; J J Schreiber; L E Nauta; F G Barr; I H Maxwell; T P Cripe Journal: Proc Natl Acad Sci U S A Date: 1997-12-23 Impact factor: 11.205
Authors: Imad Matouk; Eli Raveh; Patricia Ohana; Rasha Abu Lail; Eitan Gershtain; Michal Gilon; Nathan De Groot; Abraham Czerniak; Abraham Hochberg Journal: Int J Mol Sci Date: 2013-02-21 Impact factor: 5.923
Authors: Cristian Arriaga-Canon; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Rogelio Montiel-Manríquez; Diego Oliva-Rico; Francisco Jiménez-Trejo; Carlo Cortés-González; Luis A Herrera Journal: Oncotarget Date: 2018-04-17